Literature DB >> 12594638

Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube.

Johannes Aas1, Charles E Gessert, Johan S Bakken.   

Abstract

Clostridium difficile-associated diarrhea and colitis have emerged as major complications associated with use of systemic antimicrobials. In this study, the medical records for 18 subjects who received donor stool by nasogastric tube for recurrent C. difficile infection during a 9-year period at a single institution were retrospectively reviewed. During the period between the initial diagnosis of C. difficile colitis and the stool treatments, the 18 subjects received a total of 64 courses of antimicrobials (range, 2-7 courses; median, 3 courses). During the 90 days after receipt of treatment with stool, 2 patients died of unrelated illnesses. One of the 16 survivors experienced a single recurrence of C. difficile colitis during 90-day follow-up. No adverse effects associated with stool treatment were observed. Patients with recurrent C. difficile colitis may benefit from the introduction of stool from healthy donors via a nasogastric tube.

Entities:  

Mesh:

Year:  2003        PMID: 12594638     DOI: 10.1086/367657

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  134 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Why the human microbiome project should motivate epidemiologists to learn ecology.

Authors:  Betsy Foxman; Deborah Goldberg
Journal:  Epidemiology       Date:  2010-11       Impact factor: 4.822

3.  Fecal transplantation for the treatment of Clostridium difficile infection.

Authors:  Lawrence J Brandt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-03

Review 4.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

Review 5.  Microbiota restoration: natural and supplemented recovery of human microbial communities.

Authors:  Gregor Reid; Jessica A Younes; Henny C Van der Mei; Gregory B Gloor; Rob Knight; Henk J Busscher
Journal:  Nat Rev Microbiol       Date:  2010-11-29       Impact factor: 60.633

Review 6.  Human microbiome: From the bathroom to the bedside.

Authors:  Stephen Malnick; Ehud Melzer
Journal:  World J Gastrointest Pathophysiol       Date:  2015-08-15

Review 7.  Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation.

Authors:  Tessa M Andermann; Andrew Rezvani; Ami S Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

8.  Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients.

Authors:  R J Friedman-Moraco; A K Mehta; G M Lyon; C S Kraft
Journal:  Am J Transplant       Date:  2014-01-16       Impact factor: 8.086

9.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

10.  Clostridium difficile colitis.

Authors:  Judith L Trudel
Journal:  Clin Colon Rectal Surg       Date:  2007-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.